Posted by Michael Wonder on 11 Jan 2019
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit hyperactivity disorder
11 January 2019 - PHARMAC is pleased to announce the approval of a multi-product agreement with Teva Pharma New Zealand Limited.
This will result in the following:
- Funding a new pack size of modafinil (Modavigil), 60 tab pack, for narcolepsy in conjunction with a price decrease for the 30 tab pack, from 1 February 2019;
- Funding a new brand of methylphenidate hydrochloride extended-release tablets (Methylphenidate ER - Teva) for attention deficit and hyperactivity disorder (ADHD) subject to the same restrictions as the Concerta and Ritalin LA brands of methylphenidate hydrochloride extended-release, following Medsafe approval;
- Funding a new 40 mg formulation of glatiramer acetate (Copaxone) pre-filled syringes, which would mean fewer injections for people taking this medicine, from 1 February 2019;
- Delisting the current 20 mg formulation of glatiramer acetate (Copaxone) pre-filled syringes from 1 July 2019.
